Stock Analyst Initiations Track the latest stock analyst initiations, newly initiated coverage, and first-time analyst ratings in this regularly updated list of analyst recommendations. This page compiles new initiations, including initial stock ratings, buy/hold/sell recommendations, and price targets, so you can monitor all recent coverage openings across the market. All RatingsU.S.U.K.CanadianUpgradesDowngradesInitiationsPrice Target ChangesMore Country All Countries USA (NYSE & NASDAQ)USA (All Exchanges)CanadaUnited Kingdom Sector All Sectors AerospaceAuto/Tires/TrucksBasic MaterialsBusiness ServicesCommunication ServicesComputer and TechnologyConstructionConsumer CyclicalConsumer DefensiveConsumer DiscretionaryConsumer GoodsConsumer StaplesEnergyFinanceFinancial ServicesIndustrialsManufacturingMedicalMiscellaneousMulti-Sector ConglomeratesReal EstateRetail/WholesaleServicesTransportationUtilities Market Cap All MarketCaps Mega Cap (More Than $200B)Large Cap ($10B-$200B)Mid Cap ($2B-$10B)Small Cap ($300M-$2B)Micro Cap ($50M-$300M)Nano Cap (Under $50M) Date out of range.Reporting Date All Ratings Strong Buy Buy Hold Sell Rating By Symbol By Time Added Sort Order Export CompanyActionBrokerageAnalystCurrent PricePrice TargetRatingDetailsALNYAlnylam PharmaceuticalsInitiated by CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEric JosephSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$293.22+2.4%$380.00BuyBBIOBridgeBio PharmaInitiated by CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEric JosephSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$65.65+0.5%$82.00NeutralBMRNBioMarin PharmaceuticalInitiated by CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEric JosephSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$50.34+1.3%$75.00BuyCGONCG OncologyInitiated by Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKalpit PatelSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$63.26+0.5%Peer PerformCTMXCytomX TherapeuticsInitiated by Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating $3.59+2.4%$6.00OutperformLSPDLightspeed CommerceInitiated by Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating $8.68-3.1%$10.00UnderperformMIRMMirum PharmaceuticalsInitiated by Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKalpit PatelSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$95.32-0.2%$145.00OutperformOKLOOkloInitiated by Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSteve FleishmanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$54.58-6.8%Peer PerformPPCPilgrim's PrideInitiated by UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatheus EnfeldtSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$28.76+1.4%$30.00NeutralSTUBSTUBInitiated by CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating $9.54+2.2%Neutral ➝ Buy Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. STUBSTUBInitiated by UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating $9.54+2.2%NeutralTILEInterfaceInitiated by BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReuben GarnerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$28.07-1.6%$36.00BuyTYRATyra BiosciencesInitiated by Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKalpit PatelSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$34.52-3.2%Peer PerformXEX-EnergyInitiated by Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSteve FleishmanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$27.33+6.8%Peer PerformXEX-EnergyInitiated by TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMarc BianchiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$27.33+6.8%$35.00BuyXEX-EnergyInitiated by Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid ArcaroSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$27.33+6.8%$41.00OverweightXEX-EnergyInitiated by GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoseph OshaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$27.33+6.8%$57.00BuyXEX-EnergyInitiated by UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJon WindhamSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$27.33+6.8%$40.00BuyXEX-EnergyInitiated by Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJulien Dumoulin-SmithSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$27.33+6.8%$28.00HoldXEX-EnergyInitiated by JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJeremy TonetSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating$27.33+6.8%$38.00OverweightZETAZeta GlobalInitiated by Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating $18.41-4.1%$24.00BuyAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:12 PM ET. Frequently Asked Questions What are analyst ratings? Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives. Should you trust analyst ratings? Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell." What does an analyst rating tell you about a stock? Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere. Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
